Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model - PubMed (original) (raw)

Comparative Study

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

L S Wyatt et al. Vaccine. 1996 Oct.

Abstract

The highly attenuated, replication-deficient, modified vaccinia virus Ankara (MVA) was used to express the fusion (F) and/or hemagglutinin-neuraminidase (HN) glycoproteins of parainfluenza virus 3 (PIV3). Initial recombinant viruses in which the HN gene was regulated by a very strong synthetic earlyllate promoter replicated poorly in permissive chick embryo cells evidently due to toxic levels of the gene product. This result led us to construct and evaluate a modified earlyllate promoter derived from the H5 gene of vaccinia virus. Reporter gene experiments indicated that the enhanced H5 promoter was about five times stronger than the 7.5 promoter used in previous recombinant vaccinia/ PIV3 viruses. Although the overall expression from the modified H5 promoter was less than that of the strong synthetic promoter, early expression, determined in the presence of an inhibitor of DNA replication, was higher. Importantly, recombinant MVA employing the modified H5 promoter to regulate the F or HN gene of PIV3 replicated to high titers in chick cells and expressed functional F or HN proteins as measured by syncytial formation upon dual infection of mammalian cells. Cotton rats inoculated with recombinant MVA expressing F or HN by intramuscular or intranasal routes produced high levels of antibody. The virus expressing HN, however, was the more effective of the two in inducing immunity to PIV3 challenge, reducing PIV3 viral titers in the nasal turbinates by at least 4.7 logs and in the lungs by 3.4 logs, similar to that achieved by immunization with PIV3. These studies support further testing of recombinant MVA/PIV3 viruses as safe and effective candidate vaccines.

PubMed Disclaimer

Cited by

A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
Skiadopoulos MH, Surman SR, Riggs JM, Collins PL, Murphy BR. Skiadopoulos MH, et al. J Virol. 2001 Nov;75(21):10498-504. doi: 10.1128/JVI.75.21.10498-10504.2001. J Virol. 2001. PMID: 11581420 Free PMC article.
Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
Deschambault Y, Lynch J, Warner B, Tierney K, Huynh D, Vendramelli R, Tailor N, Frost K, Sajesh B, LeBlanc K, Layne C, Lin L, Tamming L, Beniac D, Booth S, Carpenter M, Safronetz D, Li X, Kobasa D, Cao J. Deschambault Y, et al. J Virol. 2022 May 11;96(9):e0038922. doi: 10.1128/jvi.00389-22. Epub 2022 Apr 12. J Virol. 2022. PMID: 35412347 Free PMC article.
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Bisht H, et al. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6. doi: 10.1073/pnas.0401939101. Epub 2004 Apr 19. Proc Natl Acad Sci U S A. 2004. PMID: 15096611 Free PMC article.
Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS, Haigh TA, Gudgeon NH, Phelps RJ, Lee SP, Steven NM, Rickinson AB. Taylor GS, et al. J Virol. 2004 Jan;78(2):768-78. doi: 10.1128/jvi.78.2.768-778.2004. J Virol. 2004. PMID: 14694109 Free PMC article.
Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.
Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus AD, Haagmans BL, Sutter G. Song F, et al. J Virol. 2013 Nov;87(21):11950-4. doi: 10.1128/JVI.01672-13. Epub 2013 Aug 28. J Virol. 2013. PMID: 23986586 Free PMC article.

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model - PubMed (original) (raw)